Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma (RECORD-3)

Clinical Trial ID NCT00903175

PubWeight™ 18.01^‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00903175

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma.	J Clin Oncol	2014	2.53
2	Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy.	J Hematol Oncol	2009	1.70
3	Treatment selection in metastatic renal cell carcinoma: expert consensus.	Nat Rev Clin Oncol	2012	1.19
4	Renal cell carcinoma: molecular biology and targeted therapy.	Curr Opin Oncol	2014	1.01
5	Targeted therapeutic strategies for the management of renal cell carcinoma.	Curr Opin Oncol	2012	1.00
6	Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies.	Clin Cancer Res	2011	0.95
7	NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy.	J Natl Compr Canc Netw	2011	0.94
8	Sunitinib re-challenge in advanced renal-cell carcinoma.	Br J Cancer	2014	0.93
9	Breaking through a plateau in renal cell carcinoma therapeutics: development and incorporation of biomarkers.	Mol Cancer Ther	2010	0.91
10	Everolimus - a new approach in the treatment of renal cell carcinoma.	Cancer Manag Res	2010	0.87
11	Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenib.	Biologics	2010	0.83
12	Pazopanib trial data cannot support first-line use.	Nat Rev Urol	2010	0.81
13	Fatigue in renal cell carcinoma: the hidden burden of current targeted therapies.	Oncologist	2010	0.81
14	Metastatic renal cell carcinoma: Current scenario and future trends.	South Asian J Cancer	2012	0.77
15	Review of US Comparative Economic Evidence for Treatment of Metastatic Renal Cell Carcinoma after Failure of First-Line VEGF Inhibitor Therapy.	Am Health Drug Benefits	2013	0.75
16	Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma.	Target Oncol	2011	0.75
17	Clinical experience and critical evaluation of the role of everolimus in advanced renal cell carcinoma.	Open Access J Urol	2011	0.75
18	Treatment Options in Metastatic Renal Cell Carcinoma: Focus on mTOR Inhibitors.	Clin Med Insights Oncol	2010	0.75